Clorazepate dipotassium 3.75 MG Oral Tablet — RxCUI 197465
RxNorm drug concept · Semantic clinical drug
RxCUI 197465
Semantic clinical drug · SCD
● Current RxNorm concept 18 FDA products
38 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI197465
Official nameClorazepate dipotassium 3.75 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped18
Package NDCs mapped38
Reported Medicaid activity (SDUD)13,540 prescriptions · 36 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Clorazepate: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It is used to manage anxiety disorders and give short-term relief of anxiety symptoms. It is also used as add-on treatment for partial seizures and to relieve acute alcohol withdra...
- You swallow the tablets, often split into a few doses a day for anxiety. Some people take a single dose at bedtime. Follow your prescriber's directions exactly, and do not change t...
- No. Stopping suddenly after continued use can cause withdrawal reactions, including seizures, which can be life-threatening. Your prescriber will give you a slow taper plan.
- Can I stop it suddenly if I feel better?
🕸️ Concept Web — How Clorazepate dipotassium 3.75 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Clorazepate dipotassium 3.75 MG Oral Tablet
RxCUI 197465 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Clorazepate
2353IN -
Clorazepate dipotassium
2607PIN
-
Clorazepate
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Tranxene
202966BN
-
Tranxene
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Clorazepate Oral Tablet
371589SCDF -
Clorazepate dipotassium Oral Tablet
2645890SCDFP -
Clorazepate Oral Product
1163776SCDG -
Clorazepate Pill
1163777SCDG -
Clorazepate dipotassium Oral Product
2663088SCDGP -
Clorazepate dipotassium Pill
2662458SCDGP -
Clorazepate Oral Tablet [Tranxene]
542856SBDF -
Clorazepate dipotassium Oral Tablet [Tranxene]
2657962SBDFP - +5 more in this family
-
Clorazepate Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Clorazepate dipotassium 3.75 MG
542964SCDC -
Clorazepate dipotassium 3.75 MG Oral Tablet [Tranxene]
542967SBD -
Clorazepate dipotassium 3.75 MG [Tranxene]
542966SBDC
-
Clorazepate dipotassium 3.75 MG
Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Clorazepate dipotassium 3.75 MG
SCDC · 542964 -
Clorazepate Oral Tablet
SCDF · 371589 -
Clorazepate dipotassium Oral Tablet
SCDFP · 2645890 -
Clorazepate Oral Product
SCDG · 1163776 -
Clorazepate Pill
SCDG · 1163777 -
Clorazepate dipotassium Oral Product
SCDGP · 2663088 -
Clorazepate dipotassium Pill
SCDGP · 2662458
Brand-Name Concepts
-
Clorazepate dipotassium 3.75 MG Oral Tablet [Tranxene]
SBD · 542967 -
Clorazepate dipotassium 3.75 MG [Tranxene]
SBDC · 542966 -
Clorazepate Oral Tablet [Tranxene]
SBDF · 542856 -
Clorazepate dipotassium Oral Tablet [Tranxene]
SBDFP · 2657962 -
Tranxene Oral Product
SBDG · 1179185 -
Tranxene Pill
SBDG · 1179186 -
Tranxene
BN · 202966
📦 FDA Products & Package NDCs
18 products · 38 package NDCs
38 package NDCs map to RxCUI 197465 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 13107-0282-01 | 100 TABLET in 1 BOTTLE (13107-282-01) | CLORAZEPATE DIPOTASSIUM | Aurolife Pharma LLC | 2023-09-23 |
| 13107-0282-05 | 500 TABLET in 1 BOTTLE, PLASTIC (13107-282-05) | CLORAZEPATE DIPOTASSIUM | Aurolife Pharma LLC | 2023-09-23 |
| 13107-0283-01 | 100 TABLET in 1 BOTTLE, PLASTIC (13107-283-01) | CLORAZEPATE DIPOTASSIUM | Aurolife Pharma LLC | 2023-09-23 |
| 13107-0283-05 | 500 TABLET in 1 BOTTLE, PLASTIC (13107-283-05) | CLORAZEPATE DIPOTASSIUM | Aurolife Pharma LLC | 2023-09-23 |
| 13107-0284-01 | 100 TABLET in 1 BOTTLE, PLASTIC (13107-284-01) | CLORAZEPATE DIPOTASSIUM | Aurolife Pharma LLC | 2023-09-23 |
| 13107-0319-01 | 100 TABLET in 1 BOTTLE (13107-319-01) | CLORAZEPATE DIPOTASSIUM | Aurolife Pharma LLC | 1987-07-17 |
| 13107-0319-05 | 500 TABLET in 1 BOTTLE, PLASTIC (13107-319-05) | CLORAZEPATE DIPOTASSIUM | Aurolife Pharma LLC | 1987-07-17 |
| 13107-0320-01 | 100 TABLET in 1 BOTTLE, PLASTIC (13107-320-01) | CLORAZEPATE DIPOTASSIUM | Aurolife Pharma LLC | 1987-07-17 |
| 13107-0320-05 | 500 TABLET in 1 BOTTLE, PLASTIC (13107-320-05) | CLORAZEPATE DIPOTASSIUM | Aurolife Pharma LLC | 1987-07-17 |
| 13107-0321-01 | 100 TABLET in 1 BOTTLE, PLASTIC (13107-321-01) | CLORAZEPATE DIPOTASSIUM | Aurolife Pharma LLC | 1987-07-17 |
| 51672-4042-01 | 100 TABLET in 1 BOTTLE (51672-4042-1) | Clorazepate Dipotassium | Taro Pharmaceuticals U.S.A., Inc. | 2000-04-27 |
| 51672-4042-02 | 500 TABLET in 1 BOTTLE (51672-4042-2) | Clorazepate Dipotassium | Taro Pharmaceuticals U.S.A., Inc. | 2000-04-27 |
| 51672-4042-03 | 1000 TABLET in 1 BOTTLE (51672-4042-3) | Clorazepate Dipotassium | Taro Pharmaceuticals U.S.A., Inc. | 2000-04-27 |
| 51672-4043-01 | 100 TABLET in 1 BOTTLE (51672-4043-1) | Clorazepate Dipotassium | Taro Pharmaceuticals U.S.A., Inc. | 2000-04-27 |
| 51672-4043-02 | 500 TABLET in 1 BOTTLE (51672-4043-2) | Clorazepate Dipotassium | Taro Pharmaceuticals U.S.A., Inc. | 2000-04-27 |
| 51672-4043-03 | 1000 TABLET in 1 BOTTLE (51672-4043-3) | Clorazepate Dipotassium | Taro Pharmaceuticals U.S.A., Inc. | 2000-04-27 |
| 51672-4044-01 | 100 TABLET in 1 BOTTLE (51672-4044-1) | Clorazepate Dipotassium | Taro Pharmaceuticals U.S.A., Inc. | 2000-04-27 |
| 51672-4044-02 | 500 TABLET in 1 BOTTLE (51672-4044-2) | Clorazepate Dipotassium | Taro Pharmaceuticals U.S.A., Inc. | 2000-04-27 |
| 51672-4044-03 | 1000 TABLET in 1 BOTTLE (51672-4044-3) | Clorazepate Dipotassium | Taro Pharmaceuticals U.S.A., Inc. | 2000-04-27 |
| 60505-4754-01 | 100 mg in 1 BOTTLE (60505-4754-1) | Clorazepate Dipotassium | Apotex Corp. | 2022-09-22 |
| 60505-4755-01 | 100 mg in 1 BOTTLE (60505-4755-1) | Clorazepate Dipotassium | Apotex Corp. | 2022-09-22 |
| 60505-4756-01 | 100 mg in 1 BOTTLE (60505-4756-1) | Clorazepate Dipotassium | Apotex Corp. | 2022-09-22 |
| 70954-0157-10 | 100 TABLET in 1 BOTTLE (70954-157-10) | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2022-12-16 |
| 70954-0157-20 | 30 TABLET in 1 BOTTLE (70954-157-20) | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2023-08-21 |
| 70954-0157-40 | 30 BLISTER PACK in 1 BOX, UNIT-DOSE (70954-157-40) / 1 TABL... | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2025-06-15 |
| 70954-0158-10 | 100 TABLET in 1 BOTTLE (70954-158-10) | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2022-06-16 |
| 70954-0158-20 | 500 TABLET in 1 BOTTLE (70954-158-20) | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2022-07-01 |
| 70954-0158-30 | 30 TABLET in 1 BOTTLE (70954-158-30) | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2023-08-21 |
| 70954-0158-50 | 30 BLISTER PACK in 1 BOX, UNIT-DOSE (70954-158-50) / 1 TABL... | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2025-06-15 |
| 70954-0159-10 | 100 TABLET in 1 BOTTLE (70954-159-10) | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2022-06-16 |
| 70954-0159-20 | 500 TABLET in 1 BOTTLE (70954-159-20) | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2022-07-01 |
| 70954-0159-30 | 30 TABLET in 1 BOTTLE (70954-159-30) | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2023-08-21 |
| 70954-0159-50 | 30 BLISTER PACK in 1 BOX, UNIT-DOSE (70954-159-50) / 1 TABL... | Clorazepate Dipotassium | ANI Pharmaceuticals, Inc. | 2025-06-15 |
| 72603-0112-01 | 100 TABLET in 1 BOTTLE (72603-112-01) | Clorazepate Dipotassium | NORTHSTAR RX LLC | 2022-10-24 |
| 72603-0112-02 | 500 TABLET in 1 BOTTLE (72603-112-02) | Clorazepate Dipotassium | NORTHSTAR RX LLC | 2022-10-24 |
| 72603-0113-01 | 100 TABLET in 1 BOTTLE (72603-113-01) | Clorazepate Dipotassium | NORTHSTAR RX LLC | 2022-10-24 |
| 72603-0113-02 | 500 TABLET in 1 BOTTLE (72603-113-02) | Clorazepate Dipotassium | NORTHSTAR RX LLC | 2022-10-24 |
| 72603-0114-01 | 100 TABLET in 1 BOTTLE (72603-114-01) | Clorazepate Dipotassium | NORTHSTAR RX LLC | 2022-10-24 |
Observed labelers:
ANI Pharmaceuticals, Inc. (11) ·
Aurolife Pharma LLC (10) ·
Taro Pharmaceuticals U.S.A., Inc. (9) ·
NORTHSTAR RX LLC (5) ·
Apotex Corp. (3)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.